Drug Profile
Research programme: vanilloid receptor antagonists - Ligand/Merck
Alternative Names: NGD 8695; NRGN-16Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co; Neurogen Corporation
- Class Pyridazines; Small molecules
- Mechanism of Action TRPV cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain; Urinary incontinence
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 23 Dec 2009 Preclinical development is ongoing in USA
- 08 Dec 2003 Neurogen and Merck & Co. have formed a research collaboration and combined their vanilloid receptor antagonist programmes